SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Star Scientific, Inc.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Paul Lee7/10/2012 9:49:27 AM
   of 26
 

Star Scientific Announces Allowance of Patent Claims Covering Products for Weight Loss and Reduction in Tobacco Use

GLEN ALLEN, Va., July 10, 2012 /PRNewswire/ -- Star Scientific, Inc. ( CIGX) announced that the U.S. Patent & Trademark Office (USPTO) has issued a Notice of Allowance for claims covering a product formulation that, among other uses, assists in weight loss and also the reduction of tobacco use. Application No. 12/826,985, entitled "Nutritional Product Containing Anatabine and Yerba Mate," describes and claims compositions containing a combination of anatabine and yerba mate, as well as the uses of those compositions for assisting in weight loss and in curbing the urge to use tobacco. The Notice of Allowance was issued on July 3, 2012, to Rock Creek Pharmaceuticals, the company's wholly owned subsidiary. As is typical in the patent examination process, the Notice of Allowance was issued after the company satisfactorily responded to two prior USPTO office actions. A written patent will be issued by the USPTO within the next several months.

(Logo: photos.prnewswire.com )

Paul L Perito, Esq, Chairman, President, and Chief Operating Officer of Star Scientific noted, "We are very pleased that the Patent and Trademark Office will issue a second patent to the company this year relating to anatabine and its uses. As we noted in reporting on the issuance of a patent for the synthesis of anatabine (Patent No. 8,207,346), we continue to pursue other patents relating to product formulations containing anatabine and methods of administering anatabine for the nutritional management of disorders associated with unhealthy levels of inflammation. When this patent issues, the company will have a portfolio of fifteen U.S. patents and one U.S. design patent."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext